NCT00040625Approved For Marketing不适用
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 3
研究概览
简要总结
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
- •Prior chemotherapy for your disease is allowed
- •Measurable lesion is not required
- •Have a adequate performance status
- •Sign an informed consent form
排除标准
- •You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
- •You are excluded from this trial if you have received radiation within the previous 2 weeks
- •You are excluded from this trial if you are a candidates for curative surgery
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.Lung NeoplasmsNCT00051506Eli Lilly and Company
已完成
3 期
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNon Small Cell Lung CarcinomaNCT00087711Eli Lilly and Company1,713
已完成
2 期
Pemetrexed as First Line Chemotherapy for Advanced Breast CancerBreast CancerNCT00065533Eli Lilly and Company92
已完成
1 期
Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerPrimary Peritoneal CancerOvarian CancerNCT00489359Eli Lilly and Company86
进行中（未招募）
1 期
Tratamiento con Alimta (Pemetrexed) y cisplatino como tratamiento neoadyuvante en el cancer no microcitico de pulmoCancer de Pulmon no Microcitico, Pirmera LineaEUCTR2005-002279-33-ESilly S.A.44